Market Overview on Glutamate Carboxypeptidase 2Folate Hydrolase or EC 3.4.17.21-Pipeline Review, H1 2016

Glutamate Carboxypeptidase 2Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted pipeline therapeutics.

The report provides comprehensive information on the Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit Glutamate Carboxypeptidase 2Folate Hydrolase or EC 3.4.17.21-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21)
- The report reviews Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Cerecor Inc. CureVac GmbH Eisai Co., Ltd. Inovio Pharmaceuticals, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###